Pregabalin Capsule
Product Images NDC 55700-964

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 55700-964). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (1)

Label for Pregabalin 200 mg oral capsules distributed by Quality Care Products, LLC. The package contains 60 capsules. The label includes warnings such as 'may be habit forming' and storage instructions. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. The label also shows the NDC 55700-0964-60 and a control symbol for prescription use only.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph displaying percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing the relative efficacy in pain improvement for each dosage.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent improvement in pain from baseline for patients treated with Pregabalin 100 mg three times a day versus placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. The graph depicts that a higher percentage of patients show pain improvement with Pregabalin compared to placebo across various improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line chart showing percent of patients improved plotted against percent improvement in pain from baseline. Four lines represent Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, comparing effectiveness at different pain improvement thresholds.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved by percentage improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents percent of patients improved. Three lines compare the efficacy of these treatments over the range of pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent improvement in pain from baseline against the percent of patients improved for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows three lines depicting the effectiveness of each treatment across a range of pain improvement percentages from 0 to 100%.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across various dosing groups of pregabalin and placebo in two separate studies labeled E1 and E3. The x-axis displays placebo and several pregabalin doses in mg/day, while the y-axis shows responder rate percentages. Significant differences from placebo are indicated with asterisks. The number of subjects (N) is noted below each group.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day). The graph compares four studies (E1 BD, E2 TID, E3 BD, E3 TID) using different symbols. Seizure reduction increases with dose, with significant p-values indicated at various points.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and Placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percent of patients improved, with data trends for each group plotted as distinct lines.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival graph comparing Pregabalin and placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis shows time in days. The solid line represents Pregabalin, which maintains a higher percentage of subjects without LTR compared to the dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line chart comparing the percent of subjects improved over time from baseline to week 12 BOCF for Pregabalin versus placebo. The x-axis represents percent improved from baseline, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, also ranging from 0 to 100. Pregabalin is depicted with a solid line, showing a higher percentage of subjects improved compared to placebo, which is shown with a dotted line.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph showing the percent of subjects improved for Pregabalin versus Placebo. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from greater than 0% to 100%. The y-axis shows the percent of subjects improved, ranging from 0 to 100. Two lines are plotted: a solid line for Pregabalin and a dashed line for Placebo, indicating comparative improvement over the measured range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula showing the calculation of creatinine clearance (CLcr), involving age, weight, serum creatinine levels, and an adjustment factor for female patients, likely included in dosing or pharmacokinetic information for Pregabalin capsules 200 mg by Quality Care Products.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, a human prescription drug active ingredient used in oral capsule form at 200 mg strength by Quality Care Products, LLC. The diagram depicts the molecular arrangement including amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.